These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 15191332)
21. How effective are current therapies for acromegaly? Freda PU Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744 [TBL] [Abstract][Full Text] [Related]
22. Real-world value of cabergoline in the treatment of acromegaly. Shimon I Best Pract Res Clin Endocrinol Metab; 2024 Jul; 38(4):101887. PubMed ID: 38443225 [TBL] [Abstract][Full Text] [Related]
23. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Mattar P; Alves Martins MR; Abucham J Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256 [TBL] [Abstract][Full Text] [Related]
24. Current and future medical treatments for patients with acromegaly. Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098 [TBL] [Abstract][Full Text] [Related]
25. Acromegaly: a new therapy. Friend KE Cancer Control; 2002; 9(3):232-5. PubMed ID: 12090246 [TBL] [Abstract][Full Text] [Related]
27. Newer options in the management of acromegaly. Burt MG; Ho KK Intern Med J; 2006 Jul; 36(7):437-44. PubMed ID: 16780450 [TBL] [Abstract][Full Text] [Related]
28. Current therapy and drug pipeline for the treatment of patients with acromegaly. Kumar SS; Ayuk J; Murray RD Adv Ther; 2009 Apr; 26(4):383-403. PubMed ID: 19444656 [TBL] [Abstract][Full Text] [Related]
29. Pharmacological therapy for acromegaly: a critical review. Muller AF; Van Der Lely AJ Drugs; 2004; 64(16):1817-38. PubMed ID: 15301564 [TBL] [Abstract][Full Text] [Related]
30. Cabergoline treatment in acromegaly: pros. Marazuela M; Ramos-Leví A; Sampedro-Núñez M; Bernabeu I Endocrine; 2014 Jun; 46(2):215-9. PubMed ID: 24532103 [TBL] [Abstract][Full Text] [Related]
33. Experience with pegvisomant in the treatment of acromegaly. Drake WM Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081 [TBL] [Abstract][Full Text] [Related]
34. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly]. Zgliczyński W; Zdunowski P Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736 [TBL] [Abstract][Full Text] [Related]
35. Medical therapy for acromegaly. Newman CB Endocrinol Metab Clin North Am; 1999 Mar; 28(1):171-90. PubMed ID: 10207690 [TBL] [Abstract][Full Text] [Related]
36. The use of a GH receptor antagonist in patients with acromegaly resistant to somatostatin analogs. Colao A; Pivonello R; Cappabianca P; Auriemma RS; De Martino MC; Ciccarelli A; de Divitiis E; Lombardi G J Endocrinol Invest; 2003; 26(10 Suppl):53-6. PubMed ID: 15497660 [TBL] [Abstract][Full Text] [Related]
37. [Contemporary options and perspectives in the treatment of acromegaly]. Marek J Cas Lek Cesk; 2014; 153(3):131-6. PubMed ID: 24968290 [TBL] [Abstract][Full Text] [Related]
38. Primary medical therapy for acromegaly. Sheppard MC Clin Endocrinol (Oxf); 2003 Apr; 58(4):387-99. PubMed ID: 12641619 [TBL] [Abstract][Full Text] [Related]
39. Medical management of growth hormone-secreting pituitary adenomas. Racine MS; Barkan AL Pituitary; 2002; 5(2):67-76. PubMed ID: 12675503 [TBL] [Abstract][Full Text] [Related]
40. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues. Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]